ImmuneOncia Faces Disclosure Violator Designation Over Two Late Clinical Trial Filings
Bitget2026/10/28 09:37- ImmuneOncia Therapeutics faces designation as a disclosure violator under an Oct. 28, 2026, notice; a decision is due Nov. 20, 2026.
- Late disclosures concerned clinical trial amendment application on July 1 and approval on Aug. 4; both disclosed Sept. 14, 2026.
- Final designation with at least eight penalty points could trigger a one-day trading halt.
- Annual penalty points total zero; reaching 10, including this case, could trigger a listing eligibility review.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Silver Price Forecast: XAG/USD trades flat around $53 ahead of US inflation data
Swiss Franc holds ground as US Dollar consolidates ahead of CPI inflation data
Net profit surges fivefold but masks decline in core business; crypto mining companies' shift to AI poses hidden risks
Marathon Holdings' Q3 net profit reached $632 million, up 413% year-on-year. However, its mining revenue declined by 35%. The company relied on selling 13,500 BTC to pay off debts and is now betting on AI infrastructure, increasing the risk of an imbalanced profit structure.
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Crypto prices
More
